Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction.

Cardiology and Therapy
Katherine LangLuke J Laffin

Abstract

Resistant hypertension (RH) represents an advanced subtype of hypertension that is complex to diagnose and treat. Compared with general hypertension, RH increases the risk patients will develop more advanced cardiovascular complications, including heart failure with reduced ejection fraction (HFrEF). As expected, the prevalence of RH has increased since the introduction of lower blood pressure targets included in the recent 2017 American blood pressure guidelines. The array of pharmacotherapies available to treat both hypertension and HFrEF has also expanded within the past decade. However, the efficacy of these cutting-edge pharmacotherapies has not come without a more advanced understanding of the important adjunct role non-pharmacological therapies play in helping with the management of both hypertension and HFrEF. In this review, we provide a summary of the latest pharmacological and non-pharmacological strategies that can be used to initiate treatment and optimize long-term blood pressure control in patients with coexistent RH and HFrEF.

References

Sep 11, 1992·Journal of the American College of Cardiology·R L GoldsmithJ L Fleiss
Aug 18, 1988·The New England Journal of Medicine·UNKNOWN Multicenter Diltiazem Postinfarction Trial Research Group
Nov 1, 1972·Journal of Applied Physiology·L H HartleyP T Ricketts
Jan 1, 1983·Annual Review of Physiology·C G Blomqvist, B Saltin
Jan 4, 2001·The New England Journal of Medicine·F M SacksUNKNOWN DASH-Sodium Collaborative Research Group
Nov 1, 2002·The New England Journal of Medicine·Daniel LevyRamachandran S Vasan
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Nov 13, 2004·JAMA : the Journal of the American Medical Association·George L BakrisUNKNOWN GEMINI Investigators
Nov 15, 2005·Experimental Physiology·Michael J Joyner
Apr 9, 2008·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Jacky AustinStephen Hutchison
May 6, 2008·Lancet·Carlene M M LawesUNKNOWN International Society of Hypertension
Apr 9, 2009·JAMA : the Journal of the American Medical Association·Christopher M O'ConnorUNKNOWN HF-ACTION Investigators
Dec 3, 2009·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Massimo Francesco PiepoliUNKNOWN Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Mar 2, 2012·Circulation·Stacie L DaughertyP Michael Ho
Mar 2, 2012·Circulation·Eduardo Pimenta, David A Calhoun
Jul 18, 2012·Hypertension·Fernando DimeoTimm H Westhoff
Jan 18, 2013·Journal of Hypertension·Véronique A CornelissenNeil A Smart
Mar 26, 2013·Journal of the American Heart Association·Veronique A Cornelissen, Neil A Smart
Jul 24, 2013·Circulation·Gerald F FletcherUNKNOWN American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology,
Apr 1, 2014·The New England Journal of Medicine·Deepak L BhattUNKNOWN SYMPLICITY HTN-3 Investigators
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Nov 22, 2014·The New England Journal of Medicine·Matthew R WeirUNKNOWN OPAL-HK Investigators
Nov 22, 2014·The New England Journal of Medicine·David K PackhamBhupinder Singh
Dec 30, 2014·Current Opinion in Pharmacology·Luke J Laffin, George L Bakris
Mar 12, 2015·Future Cardiology·James J DiNicolantonioJames H O'Keefe
Aug 2, 2015·European Heart Journal·Pardeep S JhundUNKNOWN PARADIGM-HF Investigators and Committees
Sep 29, 2015·Medicine and Science in Sports and Exercise·Erik H Van ItersonThomas P Olson

❮ Previous
Next ❯

Software Mentioned

SPRINT
BAROSTIM NEO
HF
ACTION
patiromer
EPHESUS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.